Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

Jasper Therapeutics announced positive Phase 1b/2a SPOTLIGHT study results for briquilimab in chronic inducible urticaria, with 92% of participants in the 180mg cohort achieving a complete response and 100% showing a clinical response. The study also demonstrated a favorable safety profile, with no serious adverse events reported and significant improvements in tryptase levels. Jasper plans to discuss these findings in a conference call on June 16, highlighting briquilimab's potential for durable symptom control in mast cell-driven diseases.

Analysis

Jasper Therapeutics (JSPR) reported promising interim results from its SPOTLIGHT Phase 1b/2a study of briquilimab in chronic inducible urticaria (CIndU). In the 180mg cohort (n=12), 92% of participants achieved a complete response (CR) and 100% achieved a clinical response, with significant reductions in tryptase levels observed in 83% of these participants. The treatment demonstrated a favorable safety profile, with no serious adverse events (SAEs) or grade 3 or higher adverse events reported in this cohort; mild, transient neutrophil count decreases were observed in 50% of participants, some potentially linked to concurrent viral infections. Across all 27 study participants, 81% achieved a CR. While these efficacy and safety data are encouraging, the small sample size of the 180mg cohort and the overall study limits definitive conclusions about broader applicability. Notably, institutional investor activity in JSPR during Q1 2025 and Q4 2024 shows a mixed sentiment, with significant divestitures by firms like BRAIDWELL LP (100% removal), SAMSARA BIOCAPITAL (100% removal), and POLAR CAPITAL (100% removal), contrasting with substantial new or increased stakes by T. ROWE PRICE (+755.3%) and UBS GROUP AG (+225.4%). This divergence suggests varying risk assessments among large investors. Two Wall Street analysts issued 'Buy' or 'Outperform' ratings in January 2025. Jasper Therapeutics plans a conference call on June 16, 2025, to further discuss these results, which will be critical for investors seeking more detailed insights into the therapy's potential for durable symptom control in mast cell-driven diseases, amidst acknowledged regulatory and market acceptance uncertainties inherent in drug development.

Key Decisions for Investors

• Investors should closely monitor Jasper Therapeutics' conference call on June 16, 2025, for additional data interpretations, management's outlook, and details on the future clinical development pathway for briquilimab.
• While the high response rates (92% CR in the 180mg cohort) and favorable safety profile are positive signals, the limited number of participants (12 in the 180mg cohort, 27 overall) warrants caution; subsequent trial data from larger patient populations will be crucial for validating these initial findings and de-risking the asset.
• The divergent institutional trading activity, with significant exits by some funds and strong entries by others, alongside positive but limited analyst coverage, suggests a need for careful individual risk assessment and due diligence on the long-term commercial viability of briquilimab, particularly considering the inherent risks associated with clinical-stage biotechnology firms.
• Consider the current positive analyst ratings but remain cognizant of the substantial risks related to regulatory approval processes and market acceptance for novel therapies, as highlighted in the company's forward-looking statements.